Home » Featured Articles » ‘Our ultimate goal is to reduce the number of Clostridium difficile infections’

‘Our ultimate goal is to reduce the number of Clostridium difficile infections’

Romy Zwittink is a researcher for the Department of Medical Microbiology at Leiden University Medical Centre and will be speaking at the NCOH Annual Scientific Meeting on 30 May 2018 on the subject of Clostridium difficile and the intestinal microbiome. We asked her three preliminary questions.

What question are you trying to answer with your research?

We are researching the relationship between the composition of the intestinal microbiota and the presence of Clostridium difficile bacteria.

Why is this important?

Clostridium difficile makes up part of the intestinal microbiota in approximately four per cent of people. When this balance is disrupted, due to the use of antibiotics, for example, Clostridium difficile can become dominant, produce toxins and cause intestinal infections. If the standard treatment does not work, and the infection recurs, transplantation of faecal microbiota may offer a solution. This treatment ensures that the levels of gut microbiota return to normal and the production of toxins by Clostridium difficile is suppressed.

Clostridium difficile can be present in the intestinal microbiota without causing disease. These ‘asymptomatic carriers’ probably play a role in spreading the bacteria in the environment and to other people, in hospitals and nursing homes, for example. We currently have too little insight into the factors influenced by asymptomatic carriers. The composition and function of the intestinal microbiota could possibly play a role.

What do you ultimately want to achieve?

Our ultimate goal is to reduce the number of Clostridium difficile infections and in doing so reduce the related morbidity and mortality. Once we know the type of composition of the gut microbiota, or which specific microorganisms suppress the colonisation or growth of Clostridium difficile, we can respond accordingly. For example, we can then select the best donor for faecal transplantation, or develop this principle further to create a supplement containing specific microorganisms to either cure or prevent Clostridium difficile infections.

More News

Masterclass Globally prepared for future outbreaks of ‘Disease X’

Leading scientists Jeremy Farrar, Marion Koopmans, and Ron Fouchier will take you into the world of new infectious diseases outbreaks and show you how we can prepare for these outbreaks.


Why do people who live near goat farms have a higher chance of developing pneumonia?

People who live in the vicinity of a goat farm have a higher chance of developing pneumonia. That was demonstrated by the study “Livestock farming and the health of neighbouring residents (VGO)”, which was carried out in Oost-Brabant and Noord-Limburg. The possible causes of this are still not known. On behalf of the Ministry of...


NCOH participates in the EU-funded project One Health European Joint Programme (One Health EJP)

NCOH Partners are involved in a recently-granted One Health European Joint Programme, which started last January. In the One Health EJP, 39 partners from 19 EU member states are gathered to create a sustainable European One Health framework by integration and alignment of medical, veterinary and food institutes through joint programming of research agendas matching...



Antimicrobial resistance (AMR) is a growing problem worldwide, and with few new drugs making it to the market, there is an urgent need for new medicines to treat resistant infections. The COMBACTE (COMBatting AntimiCrobial resisTance in Europe) project aims to give antibiotic drug development a much-needed boost by pioneering new ways of designing and implementing...